Moderna Stock News

Moderna, Inc. (NASDAQ:MRNA ) Jefferies Global Healthcare Conference Call June 5, 2025 10:30 AM ET Company Participants Stephen Hoge - President Conference Call Participants Michael Jonathan Yee - Jefferies LLC, Research Division Michael Jonathan Yee Hi, everyone. Thank you.

A few years ago, Moderna (MRNA 2.77%) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from drawing board to commercialization in less than a year and saw its stock price skyrocket.

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Tuesday that Moderna has agreed to a true placebo-controlled trial of its new COVID-19 vaccine.

The biotech's mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to vaccine rules.

Moderna's new COVID vaccine approval targets a broader high-risk population, but the market remains skeptical due to limited revenue prospects and ongoing losses. Management is pivoting to cost-cutting, pipeline focus, and realistic revenue guidance after overreaching post-pandemic and burning through cash on speculative projects. Despite leadership changes at HHS and FDA and loss of government...

U.S. equities were mixed at midday after China hit back at the U.S. and accused Washington of violating a trade deal the two countries reached last month. President Donald Trump said on Friday that China had "totally violated" the truce they struck in Geneva.

Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares edged higher after the US Food and Drug Administration (FDA) approved its newest COVID-19 vaccine mNEXSPIKE (mRNA-1283). The vaccine was approved for use in adults aged 65 and older and individuals aged 12 to 64 who have at least one underlying health risk factor as defined by the Centers for Disease Control and Prevention (CDC), Moderna said on Monday.

Moderna said mNEXSPIKE was approved by the FDA for use in adults aged 65 and up, as well as some individuals aged 12 to 64.